Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ctarc.2020.100285 http://scihub22266oqcxt.onion/10.1016/j.ctarc.2020.100285 33360669!7832265!33360669     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33360669&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Cancer+Treat+Res+Commun 2021 ; 26 (?): 100285 Nephropedia Template TP {{tp|p=33360669|t=2021. Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward |pdf=|usr=}}{{33360669}} gab.com Text Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward JO: Cancer Treat Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33360669 #FOAvip The SARS-CoV-2 (COVID-19) pandemic has particularly serious consequences for cancer patients, as they are at high risk for severe complications and mortality due to the virus since cancer patients are immunocompromised. Preliminary evidence suggests that patients with hematological, and metastatic malignancies are particularly susceptible to developing severe COVID-19 illness, which leads to poor prognosis. Biomarkers including C-reactive protein and interleukin-6 may be predictors of outcome and, therefore, crucial in assessing COVID-19 illness severity in cancer patients. A patient-specific risk and benefit inventory should be completed, and expert guidelines consulted when deciding to continue or postpone therapeutic interventions. This review presents preliminary evidence of COVID-19 infection and its impact on cancer, as well as discussion of general guidelines for the treatment and management of cancer patients with COVID-19. Twit Text FOAVip Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward ????Cancer Treat Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33360669 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33360669 #FOAvip English Wikipedia <ref>{{Cite pmid|33360669}}</ref> Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward #MMPMID33360669 Gupta K; Gandhi S; Mebane A 3rd; Singh A; Vishnuvardhan N; Patel E Cancer Treat Res Commun 2021[]; 26 (?): 100285 PMID33360669show ga The SARS-CoV-2 (COVID-19) pandemic has particularly serious consequences for cancer patients, as they are at high risk for severe complications and mortality due to the virus since cancer patients are immunocompromised. Preliminary evidence suggests that patients with hematological, and metastatic malignancies are particularly susceptible to developing severe COVID-19 illness, which leads to poor prognosis. Biomarkers including C-reactive protein and interleukin-6 may be predictors of outcome and, therefore, crucial in assessing COVID-19 illness severity in cancer patients. A patient-specific risk and benefit inventory should be completed, and expert guidelines consulted when deciding to continue or postpone therapeutic interventions. This review presents preliminary evidence of COVID-19 infection and its impact on cancer, as well as discussion of general guidelines for the treatment and management of cancer patients with COVID-19. |Biomarkers/blood[MESH] |COVID-19/*epidemiology[MESH] |Humans[MESH] |Neoplasms/*epidemiology[MESH]Cancer patients and COVID-19: Mortality, serious complications, biomar(epmc).pdf DeepDyve Pubget Overpricing